Attendees of the centennial American Heart Association (AHA) conference commend the meeting's ability to bring together diverse, interdisciplinary perspectives from across the globe.

This page features ACC's full coverage of the latest science from American Heart Association's (AHA) Scientific Sessions 2024 – including trial summaries, news stories, journal scans and more.

New science presented at AHA 2024 and simultaneously published in JACC: Advances provide insights on emerging topics such as the use of artificial intelligence (AI)-enabled left atrial (LA) volumetry ...

01上海交通大学医学院附属瑞金医院领衔的研究登上《新英格兰医学杂志》，证实更严格的收缩压目标对2型糖尿病患者的CVD有益。 02研究结果显示，收缩压＜120 mmHg的患者卒中、心梗、心衰治疗或住院以及CVD死亡风险降低了21%。

CAMZYOS was recommended by the European Society of Cardiology (ESC) in 2023 and the American College of Cardiology/American ...

Adults with chronic kidney disease (CKD) or type 2 diabetes develop cardiovascular diseases (CVD) at younger ages.

New research has found that nearly 137 million adults—or more than half of all U.S. adults—are eligible for semaglutide ...

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

The AHA established the AHA Preferred Cybersecurity Provider (APCP) Program as part of its continued commitment to support our members as they develop and implement their cybersecurity strategies and ...